Notice of FY25 Results
Arecor Therapeutics plc announced that it will release its full year results for the twelve months ended 31 December 2025 on Monday, 13 April 2026, with a webcast and Q&A for analysts and institutional investors scheduled for 9:30 AM UK time on the same day. A separate presentation for private investors will be held on the Investor Meet Company platform at 11:00 AM UK time on Thursday, 23 April 2026. The company, focused on developing therapeutics for diabetes, obesity, and cardiometabolic diseases, will share its financial performance and likely provide updates on its lead product AT278 and its oral delivery platform.
Select text to share a quote on X · sign in to keep highlights & notes in your AREC notes
Cambridge, UK, 30 March 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, will announce its full year results for the twelve months ended 31 December 2025 on Monday 13 April 2026.
Dr Sarah Howell, Chief Executive Officer, and David Ellam, Chief Financial Officer, will host a webcast and Q&A for analysts and institutional investors at 9.30am UK time on Monday 13 April 2026. To register, please contact arecor@vigoconsulting.com.
For private investors, there will be a presentation via the Investor Meet Company platform at 11.00am UK time on Thursday 23 April 2026. To register, please see https://www.investormeetcompany.com/companies/arecor-therapeutics-plc.
Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am UK time on 22 Apr 2026 or during the live presentation. Investors who follow Arecor on the Investor Meet Company platform will automatically be invited.
A copy of the full year results presentation will be released on the Company website at https://arecor.com/investor-centre/financial-information/ after the meeting on 13 April 2026.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.